

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 March 2023 (23.03.2023)



(10) International Publication Number
WO 2023/040810 A1

(51) International Patent Classification:

A61K 45/00 (2006.01) *A61K 31/4162* (2006.01)
A61K 31/435 (2006.01) *A61K 31/395* (2006.01)
A61K 31/519 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/CN2022/118351

(22) International Filing Date:

13 September 2022 (13.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/118152
14 September 2021 (14.09.2021) CN
PCT/CN2022/115148
26 August 2022 (26.08.2022) CN

(71) Applicant: **BEIGENE, LTD.** [GB/GB]; C/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, KY1-1108 (KY).

(72) Inventor; and

(71) Applicant (for SC only): **SONG, Xiaomin** [CN/CN]; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN).

(72) Inventors: **YANG, Xiao**; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN). **HU, Nan**; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN). **LIU, Yuan**; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN). **LI, Jing**; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN). **WANG, Zhiwei**; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN).

(74) Agent: **WU, FENG & ZHANG**; 3 FL, Building 2, Yard 3, FengXiuZhongLu Road, Haidian District, Beijing 100094 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

WO 2023/040810 A1

(54) Title: METHODS OF CANCER TREATMENT USING A COMBINATION OF BTK INHIBITORS AND PI3 KINASE INHIBITORS

(57) Abstract: Disclosed herein is a method for the treatment or delay of progression of cancer in a subject, comprising administering to the subject in need thereof a BTK inhibitor, for example, (S) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with a PI3K δ inhibitor or a pharmaceutically acceptable salt thereof.